4651-98-3

Usage

Uses

Used in Chemical Synthesis:
METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE is used as a reactant or intermediate for the synthesis of other chemical products. Its unique structure allows it to be involved in a variety of chemical reactions, making it a valuable component in the production of different compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE is used as a building block for the development of new drugs. Its chemical properties enable it to be incorporated into the molecular structures of potential therapeutic agents, contributing to the advancement of medicinal chemistry.
Used in Research and Development:
METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE is also utilized in research and development settings, where it serves as a key component in the exploration of new chemical reactions and the discovery of novel compounds. Its versatility in participating in various reactions makes it an essential tool for scientists and researchers in the field of chemistry.

Upstream product

• 110-89-4 piperidine 
• 55704-78-4 2,5-dihydroxy-2,5-dimethyl-1,4-dithiane 
• 105-34-0 methyl 2-cyanoacetate 
• 67-64-1 acetone 
• 6666-75-7 methyl 2-cyano-3-methylbut-2-enoate 

Downstream Products

• 75860-79-6 5-methylthieno<2,3-d>pyrimidine-2,4-dione 
• 126637-05-6 3-Allyl-2-mercapto-5-methyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 43088-64-8 5-methylthieno[2,3-d]pyrimidin-4-ol 
• 1239461-51-8 N-(4-methyl-3-(3-methyl-1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)acetamide 
• 1239461-71-2 N-(4-methyl-3-(5-methyl-4H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(4-(pyridin-4-yl)phenyl)acetamide 

Relevant academic research and scientific papers

Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands

Herein we describe the design and synthesis of a new series of heteroarylpyrimidine/heteroaryltriazine derivatives on the basis of quinazoline-2,4(1H,3H)-diones as CB2R-selective ligands using a bioisosterism strategy. An acetamide group was explored to displace the enamine linker of the lead compound for the purpose of stereoisomerism elimination and hydrophilicity increase. As a result, some of the synthesized compounds showed high bioactivity and selectivity for CB2R in calcium mobilization assays, and four displayed CB2R agonist activity, with EC50 values below 30 nm. The compound exhibiting the highest agonist activity toward CB2R (EC50=7.53±3.15 nm) had a selectivity over CB1R of more than 1328-fold. Moreover, structure–activity relationship (SAR) studies indicated that the substituents on the nucleus play key roles in the functionality of a ligand, with one such example demonstrating CB2R antagonist activity. Additionally, molecular docking simulations were conducted with the aim of better understanding of these new derivatives in relation to the structural requirements for agonists/antagonists binding to CB2R.

Heteroarylpyrimindinedione derivative and use thereof

The invention provides a heteroarylpyrimindinedione derivative and use thereof. The heteroarylpyrimindinedione derivative comprises a compound with a structure shown as general formula I, and a pharmaceutically acceptable salt or hydrate thereof. The derivative is obtained by chemical synthesis, and pharmacological experiments prove that the active ligand with cannabinoid type II receptor CB2 can be used for preparation of drugs for prevention and mitigation of CB2 receptor-mediated diseases, and the drug is cannabinoid CB2 receptor agonist's agonist, partial agonist, inverse agonist or antagonist. And the general structural formula I is shown as the specification.

Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKβ inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB. However, no inhibitory activity against IKKβ was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML.

Thienopyrimidine derivatives

4-Substituted-thieno[2,3-d], [3,2-d], and [3,4-d]pyrimidines having fungicidal, insecticidal, and miticidal utility are disclosed. Related 3-substituted-thieno[2,3-d], [3,2-d], and [3,4-d]pyrimidin-4-(3H)-imines are useful as fungicides, insecticides, and